T-DM1 demonstrated some clinical efficacy in NSCLC patients with Her-2 mutations and amplifications, but its effectiveness in Her-2 overexpressing NSCLC did not meet expectations. Here, ERBB2 is linked to non-small cell lung carcinoma.